Synapse - David Spriggs

Search Within

David R Spriggs

Results (68)

Consolidation strategies in ovarian cancer: Observations for future clinical trials

Journal Article

Sabbatini, P.; Spriggs, D.; Aghajanian, C.; Hensley, M.; Tew, W.; Konner, J.; Bell-Mcguinn, K.; Juretzka, M.; Iasonos, A.
Gynecologic Oncology (2010)

Fulltext@MSK | Save

The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment

Journal Article

O'cearbhaill, R.; Zhou, Q.; Iasonos, A.; Hensley, M. L.; Tew, W. P.; Aghajanian, C.; Spriggs, D. R.; Lichtman, S. M.; Sabbatini, P. J.
Gynecologic Oncology (2010)

Fulltext@MSK | Save

Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16

Journal Article

Dharma Rao, T.; Park, K. J.; Smith-Jones, P.; Iasonos, A.; Linkov, I.; Soslow, R. A.; Spriggs, D. R.
Applied Immunohistochemistry & Molecular Morphology (2010)

Fulltext@MSK | Save

A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer

Meeting Abstract

Konner, J. A.; Grabon, D.; Pezzulli, S.; Iasonos, A.; Sabbatini, P.; Hensley, M.; Bell-McGuinn, K.; Tew, W.; Spriggs, D.; Aghajanian, C.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies

Journal Article

Iasonos, A.; Wilton, A. S.; Riedel, E. R.; Seshan, V. E.; Spriggs, D. R.
Clinical Trials (2008)

Fulltext@MSK | Save

Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission

Journal Article

Diefenbach, C. S. M.; Gnjatic, S.; Sabbatini, P.; Aghajanian, C.; Hensley, M. L.; Spriggs, D. R.; Iasonos, A.; Lee, H.; Dupont, B.; Pezzulli, S.; more...
Clinical Cancer Research (2008)

Fulltext@MSK | Save

A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel (Tax), IP cisplatin (Cis), and IV bevacizumab (Bev) as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer

Meeting Abstract

Konner, J. A.; Fallon, K.; Pezzuli, S.; Iasonos, A.; Sabbatini, P.; Hensley, M.; Chiang, A.; Tew, W.; Spriggs, D.; Aghajanian, C.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer

Journal Article

Sabbatini, P. J.; Ragupathi, G.; Hood, C.; Aghajanian, C. A.; Juretzka, M.; Iasonos, A.; Hensley, M. L.; Spassova, M. K.; Ouerfelli, O.; Spriggs, D. R.; more...
Clinical Cancer Research (2007)

Fulltext@MSK | Save

Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy

Journal Article

Sabbatini, P.; Mooney, D.; Iasonos, A.; Thaler, H.; Aghajanian, C.; Hensley, M.; Konner, J.; Spriggs, D.; Abu-Rustum, N. R.; Dupont, J.
International Journal of Gynecological Cancer (2007)

Fulltext@MSK | Save

A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission

Journal Article

Levine, D.; Park, K.; Juretzka, M.; Esch, J.; Hensley, M.; Aghajanian, C.; Lewin, S.; Konner, J.; Derosa, F.; Spriggs, D.; more...
Cancer (2007)

Fulltext@MSK | Save